Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review

• Published in: American journal of physiology: endocrinology and metabolism Vol. 326; no. 4; pp. E417 - E427
• Main Authors: Gindri, Izabelle de Mello, Ferrari, Gustavo, Pinto, Luiz Paulo S, Bicca, Juliana, Dos Santos, Isis Kelly, Dallacosta, Darlan, Roesler, Carlos Rodrigo de Mello
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.04.2024
• Subjects: Adenine; Adenosine triphosphate; Alzheimer's disease; Anxiety; ATP; Bias; Biological activity; Calcium; Cerebrospinal fluid; Chronic fatigue syndrome; Clinical trials; Coenzymes; DNA repair; Evaluation; Fatigue; Fatigue tests; Gene expression; Heart rate; Inflammation; Insulin; Movement disorders; Muscles; Muscular fatigue; NAD; NADH; Neurodegenerative diseases; Nicotinamide; Nicotinamide adenine dinucleotide; Nucleotides; Older people; Oral administration; Oxidative phosphorylation; Parkinson's disease; Phosphorylation; Post-menopause; Pyridines; Quality of life; Risk; Search engines; Serum; Side effects; Sleep; Systematic review; NAD; effectiveness; NADH; safety
• ISSN: 0193-1849; 1522-1555; 1522-1555
• DOI: 10.1152/ajpendo.00242.2023

Nicotinamide adenine dinucleotide (NAD ) is an essential pyridine nucleotide cofactor that is present in cells and in several important biological processes, including oxidative phosphorylation and production of adenosine triphosphate, DNA repair, calcium-dependent secondary messenger and gene expression. The purpose of this systematic review is to examine whether the coenzyme formulae NAD and NADH are safe and effective when acting as a supplement to humans. This systematic review of randomized clinical trials performed a search in six electronic databases: PubMed, MEDLINE ( ), Embase, Cochrane CENTRAL (clinical trials), Web of Science, and Scopus. Secondary search included the databases (e.g., Clinical trials.gov, Rebec, Google Scholar - advance). Two reviewers assessed and extracted the studies independently. The risk of bias in studies was performed using version 2 of the Cochrane risk of bias tool for randomized trials. This review includes 10 studies, with a total of 489 participants. The studies included different clinical conditions, such as chronic fatigue syndrome (CFS), older adults, Parkinson's disease, overweight, postmenopausal prediabetes, and Alzheimer's disease. Based on studies, the supplementation with NADH and precursors was well tolerated and observed clinical results such as, a decrease in anxiety conditions and maximum heart rate was observed after a stress test, increased muscle insulin sensitivity, insulin signaling. Quality of life, fatigue intensity, and sleep quality among others were evaluated on patients with CFS. All studies showed some side effects, thus, the most common associated with NADs use are muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches. All adverse events cataloged by the studies did not present a serious risk to the health of the participants. Overall, these findings support that the oral administration of NADH can be associated to an increase in general quality of life and improvement on health parameters (e.g., a decrease in anxiety, maximum heart rate, inflammatory cytokines in serum, and cerebrospinal fluid). NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered.